The CD34+ bone marrow cells of AML patients with high expression of NOTCH2 splice variant had decreased mRNA expression of NOTCH targets HES1, HEY1 and DTX1 compared with CD34+ AML cells expressing full length NOTCH2. This suggests that the expression of NOTCH2 splice variants have oncogenic potential and results in the inactivation of NOTCH pathway and this process might be contributing to AML pathology (Adamia et al. 2014). This evidence concerns the gene CD34 and acute myeloid leukemia.